Figure 3. sEH inhibition decreased fasting glucose levels in type 2 diabetic mice.

Fasting blood glucose levels were obtained from control and HFD+STZ/NA mice before (A) and after (B) treatment with the sEH inhibitor t-AUCB (1 mg/kg i.p. daily, 7 days) or vehicle. C) Serum insulin levels were also measured in t-AUCB or vehicle treated mice 24 h after ischemia. *p<0.001 vs. Control Vehicle, #p<0.05 vs. HFD+STZ/NA Vehicle. A) n = 20–22 per group. B) n = 5–8 per group. C) n = 2–6 per group.